Here, we used three different drugs (SRPIN340 (SRPK inhibitor), TG003 (CLK inhibitor), and EPZ015666 (PRMT5 inhibitor)) in CML cell lines and in primary CP-CML cell samples. This evidence concerns the gene PRMT5 and chronic myelogenous leukemia, BCR-ABL1 positive.